January 18th 2023
Highly effective medications for severe disease are expensive and administered invasively, while the development of treatments for milder disease has lagged, a new review on psoriasis clinical trials concludes.
September 20th 2022
Precision medicine may help improve the diagnosis and management of melanoma.
September 14th 2022
A new study highlights the ways genetic testing and profiling can be extended to help diagnose and treat a variety of conditions—even rashes.
August 15th 2022
The amount of transcriptomic data available for psoriasis may prove helpful in treating the condition through a precision medicine approach.
August 4th 2022
Studies show that patients with atopic dermatitis may benefit from a multidisciplinary approach.
Atopic Dermatitis: A Personalized Approach May Improve Outcomes
Precision medicine offers better results while treating severe atopic dermatitis.
Patch Effective in Extracting Transcriptomes for Precision Medicine in Psoriasis
Minimally invasive method outperformed tape stripping in a recent study.
The Precision Medicine Revolution
The most critical step is understanding what value precision medicine brings to your practice, and where it can have greatest impact from both a clinical and business perspective.
Examining Cells in Inflammatory Skin Disease
A recent study dove into how precision medicine can be used to better target inflammatory skin disease and provide physicians with better treatment regimens.
Mindera Health Pilot Program to Improve Psoriasis Management
Mindera Health and a national health insurance company launched a pilot program to improve moderate-to-severe psoriasis management with precision medicine.
Precision Medicine Test for Psoriasis Predicts Response Rate to Biologics
Recent data tracks the first realization of precision medicine for patients with psoriasis.
POLL: Are You Looking Forward to More Bio-similars on the Market?
Click here to answer this weeks poll.
Biosimilars for Humira Are on Their Way
In 2023 as many as 11 biosimilars to Humira are headed for the US market.
Amgen Releases Positive Phase 3 Results for Stelara Biosimilar
A phase 3 study conducted by Amgen found that the company’s ustekinumab biosimilar was as safe and efficacious as the reference product (Stelara) in patients with moderate to severe plaque psoriasis.
Optimize Off-Label Use of Biologics and New Medications
Experts explored out-of-the-box solutions for treating challenging skin and hair disorders at the American Academy of Dermatology (AAD)’s 2022 Annual Meeting held March 25 to 29, 2022, in Boston, Massachusetts.
Dupilumab Receives FDA Priority Review and Accepts sBLA for Children 6 Months to 5 Years
If approved, dupilumab will be the first biologic medicine available in the US to treat uncontrolled moderate to severe atopic dermatitis for young children 6 months to 5 years old.
Biologics Offer Range of Options for Dermatologists Looking to Treat Patients
Studies offer positive outcomes for patients with conditions like hidradenitis suppurativa or psoriasis.
Secukinumab Receives FDA Approval for Pediatric Patients with PsA
Secukinumab is the only biologic treatment in the US that’s approved by the FDA for pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).
New Frontiers in Psoriatic Disease Research
An article published in the Journal of Investigative Dermatology examined genetic, environmental triggers, immunology, pathophysiology, and precision medicine in psoriasis.
The Potential of Precision Medicine
Taking the polar opposite of a one-size-fits-all approach, clinicians now factor in a patient’s genetic profile, medical history, microbiome composition, lifestyle, and diet, among other parameters, otherwise known as precision medicine.